•,				JCO4 Rec'd PCT/PTO 3 0 May 200				
	PRM PTC EV 1-20	2000)						
1/1	4		ER TO THE UNITED STATES	U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5)				
V	1	CONCERNING A FIL	CTED OFFICE (DO/EO/US) LING UNDER 35 U.S.C. 371	10/069,598				
INT	ΓERNA	ATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED				
<u></u>		PCT/JP00/06172	08/09/2000	08/09/1999				
		F INVENTION						
	MATERIAL FOR USE IN EXTRACORPOREAL CIRCULATION, ADSORBENT, REMOVAL UNIT AND REMOVING METHOD FOR DIABETIC COMPLICATION FACTORS							
AP	APPLICANT(S) FOR DO/EO/US							
<u> </u>	<u> </u>		SHIMIZU et al					
Apı	plicant			O/US) the following items and other information:				
1.		This is a FIRST submission	of items concerning a filing under 35 U.S.C.	2. 371.				
2.	\boxtimes		SEQUENT submission of items concerning a					
3.		This is an express request to items (5), (6), (9) and (21) i	o begin national examination procedures (3findicated below.	55 U.S.C. 371(f)). The submission must include				
4.		The U.S. has been elected I	by the expiration of 19 months from the prior	rity date (Article 31).				
5.	A co		eation as filed (35 U.S.C. 371(c)(2)).					
	a.	is attached hereto (req	quired only if not communicated by the Intern	national Bureau).				
	b.	has been communicate	ed by the International Bureau.					
	C.	is not required, as the	application was filed in the United States Re	eceiving Office (RO/US).				
6.		An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).						
	a.	is attached hereto.						
	b.	has been previously su	ubmitted under 35 U.S.C. 154(d)(4).					
7.		Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))						
	a.		equired only if not communicated by the Inter					
	b.	have been communicate	ited by the International Bureau.					
	C.	have not been made; h	nowever, the time limit for making such amen	ndments has NOT expired.				
ı	d.	have not been made ar	nd will not be made.					
8.		An English language translaf	tion of the amendments to the claims under	PCT Article 19 (35 U.S.C. 371(c)(3)).				
9.			inventor(s) (35 U.S.C. 371(c)(4)).					
10.		A English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).						
	Item	s 11 To 20 below concern o	document(s) or information included:					
11.		An Information Disclosure St	tatement under 37 C.F.R. 1.97 and 1.98.					
12.		An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.						
13.		A FIRST preliminary amendment.						
14.	\boxtimes	A SECOND or SUBSEQUEN	IT preliminary amendment.					
15.		A substitute specification.						
16.		A change of power of attorne	y and/or address letter.					
17.		A computer-readable form of	the sequence listing in accordance with PC	T Rule 13ter.2 and 35 U.S.C. 1.821-1.825.				
18.			lished international application under 35					
19.			n language translation of the international app					
20. Missi		Other items or information. S		CODY of Sequence Listing: Copy of Notification of				

U.S. APPLICATION NO. (If known, see 37 C.F.As)		.5)				ATTORNEY'S DOCKET NUMBER 2109-24			
			PCT/JP00/0617	2			ALCULATIONS	DT	O USE ONLY
21. The following fees are submitted:						14	ALCULATIONS	-	J USE CINLY
BASIC NATIONAL FEE (37 C.F.R. 1.492(a)(1)-(5): Neither international preliminary examination fee (37 C.F.R. 1.482) nor international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO\$1040.00									
International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO\$890.00									
International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO									
International preliminary examination fee (37 C.F.R. 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)									
	·		ENTER APPROPRIATE	BASIC FEE	= TRUOMA	\$	0.00		
months from the earliest	claimed priority	date (37 0				\$	0.00		
CLAIMS	NUMBER F		NUMBER EXTRA		ATE			r	
Total Claims	20	-20 =	0	X	\$18.00	\$	0.00	 	
Independent Claims	3	-3 =	0	X	\$84.00		0.00	├—	
MULTIPLE DEPENDENT	CLAINS(S) (II	аррисавіє	TOTAL OF AB		BO.00	\$ \$	0.00 0.00	 	
Applicant claims sm are reduced by 1/2.		See 37 (CFR 1.27. The fees indica		DEATIONS -	Ť	0.00		
4.0 1.002000 57 1.721				S	UBTOTAL =	\$	0.00	<u> </u>	
Processing fee of \$130.0 months from the earliest] 20 30 +			0.00		
					ONAL FEE =	\$	0.00		
accompanied by an appr	opriate cover sh	eet (37 C.	F.R. 1.21(h)). The assignr F.R. 3.28, 3.31). \$40.00 j	per property	+	\$	0.00		
Fee for Petition to Revive	<u>Unintentionally</u>	Abandon	ed Application (\$1280.00			\$	0.00		
			101	AL FEES E	NCLOSED =	\$	0.00		r
						A	mount to be: refunded	\$	Į
						\vdash	Charged	\$	
 a. A check in the amount of \$0.00 to cover the above fees is enclosed. b. Please charge my Deposit Account No. 14-1140 in the amount of \$ to cover the above fees. A duplicate copy of this form is enclosed. 									
			to charge any additional fo			, or	credit any		
overpayment to Deposit Account No. <u>14-1140</u> . A <u>duplicate</u> copy of this form is enclosed. d.									
NOTE: Where an appropriate time limit under 37 C.F.R. 1.494 or 1.495 has not been met a petition to revive (37 C.F.R. 1.137(a)									
or (b)) must be filed and granted to restore the application to pending status.									
SEND ALL CORRESPONDENCE TO:						·			
NIXON & VANDERHYE P.C. 1100 North Glebe Road, 8 th Floor									
Arlington, Virginia 22201-4714 Telephone: (703) 816-4000 Arthur R. Crawford									
ARC:eaw NAME									
				25,327			May 30, 20	02	
					RATION NUMBE	R	Date		





UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patients, Box PCT United States Patient and Tradsmark Office Washington, D.C., 20233

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATT	ATTY, DOCKET NO.			
10/069,598	S. Shimizu		2109-24 IERNATIONAL APPLICATION NO. PCT/JP00/06172			
		INTERNATIONAL AP				
		PCT/JP00/				
Arthur R Crawford	I.A. FILING DATE	PRIORITY DATE				
Nixon & Vanderhye	_	08/09/2000	09/08/1999			

Nixon & Vanderhye 1100 North Glebe Road 8th Floor Arlington, VA 22201-4714

CONFIRMATION NO. 3579
371 FORMALITIES LETTER
OC000000007973332

Date Mailed: 04/29/2002

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- . U.S. Basic National Fees
- Priority Document
- Assignee Statement
- Biochemical Sequence Listing
- · Copy of IPE Report
- · Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- · Oath or Declaration
- · Preliminary Amendments
- Request for Immediate Examination

DOCKETED

CLT/MATTER# 2100	7-24
MAIL DATE 4/29/2	
DUE DATE JUME	29,2002
FINAL DEADLINE TOU	29,2002
DOCKETED BY MG	Page .
	(a

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

• The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the

requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):



- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase Patentin Software, call (703) 306-2600
 - For Patentln Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

PATRICIA A BOOKER

Telephone: (703) 305-3738

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.			
10/069,598	РСТ/JР00/06172	2109-24			

FORM PCT/DO/EO/905 (371 Formalities Notice)